Clinical Trial Update: Clinical Study to Evaluate the Maximum Tolerated Dose of BAY79-4620 Given Every 2 Weeks to Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 trial update reports the termination of a study evaluating BAY79-4620 administered every two weeks in patients with advanced solid tumors. The update …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• BAY79-4620

Snippet

Sponsor: Bayer | Conditions: Neoplasms | Phase 1 | Status: TERMINATED